甲状腺微小乳头状癌中央区淋巴结转移的高危因素

摘要/Abstract

摘要：近年来，大量研究发现甲状腺微小乳头状癌（PTMC）的中央区淋巴结转移与一些危险因素明显相关，如年龄≤45岁、BRAF基因突变、血管内皮生长因子C过度表达、癌灶直径≥5 mm、多发病灶及双侧病灶、病灶侵犯甲状腺包膜等。这些高危因素参与疾病的进程，并且相互影响。对高危因素的研究有助于预测患者发生中央区淋巴结转移的风险，从而有效地指导患者治疗。

关键词:甲状腺肿瘤,淋巴结,危险因素

Abstract:In recent years, a large number of studies have found that central lymph node metastasis of the papillary thyroid microcarcinoma (PTMC) is significantly related with some risk factors. These high risk factors include age below 45 years old, BRAF gene mutation, vascular epithelial growth factorC high expression, tumor diameter≥5 mm, multifocal and bilateral tumor, thyroid capsule invasion and so on. These high risk factors involve in disease process, and interact with each other. The studies of the high risk factors can help us to predict the risk of central lymph node metastasis in the patients with PTMC, thus to effectively guide the patients′ treatment.

Key words:Thyroid neoplasms,Lymph nodes,Risk factors

李耀,王圣应. 甲状腺微小乳头状癌中央区淋巴结转移的高危因素[J]. 国际肿瘤学杂志, 2016, 43(1): 42-44.

Li Yao, Wang Shengying. High risk factors related to central lymph node metastasis in papillary thyroid microcarcinoma[J]. Journal of International Oncology, 2016, 43(1): 42-44.

参考文献

［1］ Soares P, Celestino R, Gaspar da Rocha A, et al. Papillary thyroid microcarcinoma: how to diagnose and manage this epidemic?［J］. Int J Surg Pathol, 2014, 22(2): 113-119. DOI:10.1177/1066896913517394. ［2］ Kim YS. Patterns and predictive factors of lateral lymph node metastasis in papillary thyroid microcarcinoma［J］. Otolaryngol Head Neck Surg, 2012, 147(1): 15-19. DOI:10.1177/0194599812439277. ［3］ Zhou YL, Gao EL, Zhang W, et al. Factors predictive of papillary thyroid microcarcinoma with bilateral involvement and central lymph node metastasis: a retrospective study［J］. World J Surg Oncol, 2012, 10: 67-67. DOI: 10.1186/1477-7819-10-67. ［4］ Lu ZZ, Zhang Y, Wei SF, et al. Outcome of papillary thyroid microcarcinoma: study of 1 990 cases［J］. Mol Clin Oncol, 2015, 3(3): 672676. DOI:10.3892/mco.2015.495. ［5］ Li X, AbdelMageed AB, Kandil E. BRAF mutation in papillary thyroid carcinoma［J］. Int J Clin Exp Med, 2012, 5(4): 310-315. ［6］ Lin KL, Wang OC, Zhang XH, et al. The BRAF mutation is predictive of aggressive clinicopathological characteristics in papillary thyroid microcarcinoma［J］. Ann Surg Oncol, 2010, 7(12): 3294-3300. DOI:10.1245/s10434-010-1129-6. ［7］ Nucera C, Pontecorvi A. Clinical outcome, role of BRAF(V600E), and molecular pathways in papillary thyroid microcarcinoma: is it an indolent cancer or an early stage of papillary thyroid cancer?［J］. Front Endocrinol (Lausanne), 2012, 3: 33-33. DOI:10.3389/fendo.2012.00033. ［8］ Yan LI, Li LI, Li Q, et al. Expression of signal transducer and activator of transcription 3 and its phosphorylated form is significantly upregulated in patients with papillary thyroid cancer［J］. Exp Ther Med, 2015, 9(6): 2195-2201. DOI:10.3892/etm.2015.2409. ［9］ Zhang L, Wei WJ, Ji QH, et al. Risk factors for neck nodal metastasis in papillary thyroid microcarcinoma: a study of 1 066 patients［J］. J Clin Endocrinol Metab, 2012, 97(4): 1250-1257. DOI:10.1210/jc.2011-1546. ［10］ Zhang LY, Liu ZW, Liu YW, et al. Risk factors for nodal metastasis in cN0 papillary thyroid microcarcinoma［J］. Asian Pac J Cancer Prev, 2015, 16(8): 3361-3363. ［11］ Lee KJ, Cho YJ, Kim SJ, et al. Analysis of the clinicopathologic features of papillary thyroid microcarcinoma based on 7mm tumor size［J］. World J Surg, 2011, 35(2): 318-323. DOI:10.1007/s00268-010-0886-5. ［12］ Liu Z, Wang L, Yi P, et al. Risk factors for central lymph node metastasis of patients with papillary thyroid microcarcinoma: a metaanalysis［J］. Int J Clin Exp Pathol, 2014: 7(3): 932-937. ［13］ Kim BY, Jung CH, Kim JW, et al. Impact of clinicopathologic factors on subclinical central lymph node metastasis in papillary thyroid microcarcinoma［J］. Yonsei Med J, 2012, 53(5): 924-930. DOI:10.3349/ymj.2012.53.5.924. ［14］ Chung YJ, Lee JS, Park SY, et al. Histomorphological factors in the risk prediction of lymph node metastasis in papillary thyroid carcinoma［J］. Histopathology, 2013, 62(4): 578-588. DOI:10.1111/his.12025. ［15］ Lombardi CP, Bellantone R, De Crea C, et al. Papillary thyroid microcarcinoma: extrathyroidal extension, lymph node metastases, and risk factors for recurrence in a high prevalence of goiter area［J］. World J Surg, 2010, 34(6): 1214-1221. DOI:10.1007/s00268-009-0375-x. ［16］ Ardito G, Revelli L, Giustozzi E, et al. Aggressive papillary thyroid microcarcinoma: prognostic factors and therapeutic strategy［J］. Clin Nucl Med, 2013, 38(1): 25-28. DOI: 10.1097/RLU.0b013e318279bc65. ［17］ Zhao Q, Ming J, Liu C, et al. Multifocality and total tumor diameter predict central neck lymph node metastases in papillary thyroid microcarcinoma［J］. Ann Surg Oncol, 2013, 20(3): 746752. DOI: 10.1245/s1043401226542. ［18］ So YK, Kim MW, Son YI. Multifocality and bilaterality of papillary thyroid microcarcinoma［J］. Clin Exp Otorhinolaryngol, 2015, 8(2): 174-178. DOI:10.3342/ceo.2015.8.2.174. ［19］ Xu D, Lv X, Wang S, et al. Risk factors for predicting central lymph node metastasis in papillary thyroid microcarcinoma［J］. Int J Clin Exp Pathol, 2014, 7(9): 6199-6205. ［20］ Ito Y, Kudo T, Kobayashi K, et al. Prognostic factors for recurrence of papillary thyroid carcinoma in the lymph nodes, lung, and bone: analysis of 5 768 patients with average 10year followup［J］. World J Surg, 2012, 36(6): 12741278. DOI:10.1007/s0026801214235. ［21］ Wan HF, Zhang B, Yan DG, et al. The BRAFT1799A mutation is not associated with occult contralateral carcinoma in patients with unilateral papillary thyroid microcarcinoma［J］. Asian Pac J Cancer Prev, 2015, 16(7): 2947-2951. ［22］ Ma YJ, Deng XL, Li HQ. BRAF (V600E) mutation and its association with clinicopathological features of papillary thyroid microcarcinoma: a meta-analysis［J］. J Huazhong Univ Sci Technolog Med Sci, 2015, 35(4): 591599. DOI:10.1007/s11596-015-1476-4. ［23］ Connor MP, Wells D, Schmalbach CE. Variables predictive of bilateral occult papillary microcarcinoma following total thyroidectomy［J］. Otolaryngol Head Neck Surg, 2011, 144(2): 210-215. DOI:10.1177/0194599810391616.

[1]	刘静, 刘芹, 黄梅.基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[2]	王子琪, 罗盼, 叶永英, 吴伟莉.甲状腺腺样囊性癌1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(3): 191-192.
[3]	赵鑫, 范学武, 田龙, 胡逸民.三维超声在前列腺癌图像引导放疗中的应用与评价研究[J]. 国际肿瘤学杂志, 2024, 51(1): 43-49.
[4]	邓隽军, 赵大勇, 李淼.免疫检查点抑制剂在非小细胞肺癌治疗中的不良反应及危险因素[J]. 国际肿瘤学杂志, 2023, 50(9): 564-568.
[5]	张劲男, 刘邦卿, 李军, 刘晓辉.BHLHE40靶向HMGA2激活氧化磷酸化通路降低甲状腺癌细胞对顺铂敏感性的研究[J]. 国际肿瘤学杂志, 2023, 50(7): 398-406.
[6]	凡梦思, 陆雅萍, 闫莉.子宫内膜癌前哨淋巴结假阴性患者的临床病理特征分析[J]. 国际肿瘤学杂志, 2023, 50(5): 274-279.
[7]	杨丽蓉, 王羽丰.预测浆液性卵巢癌术后复发远处转移风险机器学习模型的构建[J]. 国际肿瘤学杂志, 2023, 50(4): 220-226.
[8]	曹梦清, 徐志勇, 施毓婷, 王凯.三级淋巴结构在肿瘤免疫微环境调节和抗肿瘤治疗中的作用[J]. 国际肿瘤学杂志, 2023, 50(3): 169-173.
[9]	焦盼盼, 薛丽娟, 詹娟.免疫检查点抑制剂相关不良反应的危险因素与预测因素[J]. 国际肿瘤学杂志, 2023, 50(12): 739-744.
[10]	朱琪伟, 崔娟娟, 张紫寒, 杨燕光, 葛彬彬, 刘于, 储开岳.左侧乳腺癌术后内乳区域淋巴结照射的心脏剂量学分析和生命质量评估[J]. 国际肿瘤学杂志, 2023, 50(1): 17-21.
[11]	王熠昕, 曹蒙, 王焱.国产纳米炭混悬液在恶性肿瘤前哨淋巴结活检中的应用进展[J]. 国际肿瘤学杂志, 2023, 50(1): 22-27.
[12]	杨莎, 杨晓华, 王苏华, 薛晓燕, 徐俊.老年肺癌胸腔镜手术后下肢深静脉血栓的危险因素分析及预测模型的建立和验证[J]. 国际肿瘤学杂志, 2022, 49(9): 532-536.
[13]	张艳, 潘磊, 刘树亭.基于ABCB1和ABCG2基因多态性建立非小细胞肺癌患者吉非替尼疗效预测模型[J]. 国际肿瘤学杂志, 2022, 49(6): 327-333.
[14]	朱一硕, 崔玉洁, 刘崎, 李军, 范月超.脑胶质瘤患者术后早期复发危险因素分析及预测模型构建[J]. 国际肿瘤学杂志, 2022, 49(2): 79-83.
[15]	李劲浩, 王桂东, 李雪菲, 刘子琳, 孟凯龙.静脉期CT值预测甲状腺乳头状癌中央组淋巴结转移的临床研究[J]. 国际肿瘤学杂志, 2022, 49(10): 581-585.